Serum vascular endothelial growth factor and interleukin-6 in colorectal cancer.
作者信息
Alzoghaibi Mohammad
出版信息
Saudi J Gastroenterol. 2011 May-Jun;17(3):163-4. doi: 10.4103/1319-3767.80376.
Abstract
摘要
相似文献
1
Serum vascular endothelial growth factor and interleukin-6 in colorectal cancer.
Saudi J Gastroenterol. 2011 May-Jun;17(3):163-4. doi: 10.4103/1319-3767.80376.
2
Determination of IL-6, TNF-α and VEGF levels in the serums of patients with colorectal cancer.
Cell Mol Biol (Noisy-le-grand). 2017 May 20;63(5):97-101. doi: 10.14715/cmb/2017.63.5.18.
3
Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.
BMC Cancer. 2010 May 14;10:203. doi: 10.1186/1471-2407-10-203.
4
Relationship between loneliness and proangiogenic cytokines in newly diagnosed tumors of colon and rectum.
Psychosom Med. 2010 Nov;72(9):912-6. doi: 10.1097/PSY.0b013e3181f0bc1c. Epub 2010 Aug 17.
5
Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer.
Saudi J Gastroenterol. 2011 May-Jun;17(3):170-3. doi: 10.4103/1319-3767.80378.
6
The role of vascular endothelial growth factor, tumor necrosis factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy.
Diabetes Res Clin Pract. 2008 Jan;79(1):141-6. doi: 10.1016/j.diabres.2007.07.011. Epub 2007 Aug 22.
7
[Perioperative immunologic changes in colorectal cancer patients].
Chirurgia (Bucur). 2012 Jan-Feb;107(1):59-65.
8
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
Basic Clin Pharmacol Toxicol. 2007 Jun;100(6):387-91. doi: 10.1111/j.1742-7843.2007.00065.x.
9
[Clinical value of preoperative serum VEGF, CRP and IL-6 levels in colorectal carcinoma].
Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):795-9.
10
Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Dis Colon Rectum. 2009 May;52(5):993-9. doi: 10.1007/DCR.0b013e31819ed3bc.
本文引用的文献
1
Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).
Mol Med Rep. 2011 Mar-Apr;4(2):203-8. doi: 10.3892/mmr.2010.408. Epub 2010 Dec 16.
2
Cytokines, inflammation and colon cancer.
Curr Cancer Drug Targets. 2011 May;11(4):451-64. doi: 10.2174/156800911795538066.
3
Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs.
Gastroenterology. 2011 Mar;140(3):799-808, quiz e11. doi: 10.1053/j.gastro.2010.11.041. Epub 2010 Nov 27.
4
Serum interleukin-6 levels in colorectal cancer patients--a summary of published results.
Int J Colorectal Dis. 2010 Feb;25(2):135-40. doi: 10.1007/s00384-009-0818-8. Epub 2009 Nov 7.
5
Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis.
J Thorac Oncol. 2009 Sep;4(9):1094-103. doi: 10.1097/JTO.0b013e3181a97e31.
6
Inflammation and colorectal cancer.
Curr Opin Pharmacol. 2009 Aug;9(4):405-10. doi: 10.1016/j.coph.2009.06.006. Epub 2009 Jul 7.
7
Inflammation and cancer: IL-6 and STAT3 complete the link.
Cancer Cell. 2009 Feb 3;15(2):79-80. doi: 10.1016/j.ccr.2009.01.009.
8
Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis.
Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G850-9. doi: 10.1152/ajpgi.00071.2008. Epub 2009 Jan 29.
9
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
Ann Oncol. 2008 Oct;19(10):1734-41. doi: 10.1093/annonc/mdn368. Epub 2008 Jun 11.
10
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.
J Clin Oncol. 2008 Feb 20;26(6):856-62. doi: 10.1200/JCO.2007.13.5947.
Zotero 插件